Isodiol International Inc. Announces Partnership Between ISO-Sport and ALTIS, an Elite Training Environment for Athletes & Coaches

Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global CBD leader and innovator is pleased to announce that Iso-Sport has entered into an agreement with ALTIS LLC (“Altis”), an Arizona based company that was built to bring Track & Field back to global prominence through multi-disciplinary unification of the sport, to create the “Iso-Sport Living Lab” and investigate the impact of CBD on various areas of athlete health and performance.

Altis provides an environment in which elite athletes can thrive by providing coaching, integrated support services, education, and a complete athlete experience. The company helps shape the careers of many of the best athletes in the world and build championship performers. Altis is committed to an education program that nurtures and develops both coaches and athletes within its sport, assuring professionalism and continued growth at all levels of athletic development.

Through this relationship, Altis will work closely with Iso-Sport to focus on the research and development of CBD products for performance, recovery, and sleep.  Specifically, the companies intend to:

• Design and implement a substantial designated area within a primary Altis track and field facility that is dedicated to sports science and named the “Iso-Sport Living Lab”;
• Produce or facilitate at least one research study per year investigating the impact of CBD on various areas of athlete health and performance; and
• Publish one or more articles on the Altis website on the scientifically demonstrated benefits of CBD in the various areas of athlete health and performance.
• Altis will distribute and sell Iso-Sport CBD performance products through its retail and wholesale distribution channels.

“Altis is home to over 100 athletes and Olympians from 30 different countries. Together, we hope to develop innovative products that will improve the recovery and performance of athletes and show consumers around the world the benefits of CBD in sports.  With the World Anti-Doping Agency’s (WADA) removal of cannabidiol ( CBD ) from their List of Prohibited Substances and Methods in January 2018, Isodiol and Iso-Sport are positioned to capitalize on opportunities with athletes across the world,” said Isodiol CEO, Marcos Agramont.

“With the introduction of the Altis: Iso-Sport Living Lab, we aim to generate new scientific data and knowledge by exploring, experimenting, and evaluating new ideas within the natural sporting ecosystem.  Altis is building a community of innovative, multi-disciplinary, and collaborative partnerships with educational institutions, private businesses, coaches, researchers, and athletes with the goal of, quite simply, changing the way sport science is done by turning the real world into a laboratory.  This new relationship with Isodiol and Iso-Sport and the companies’ innovation with CBD products is a great step forward toward our goals,” said Altis CEO, Stuart McMillan.

As part of this relationship, Isodiol will make an initial cash payment to Altis of US$225,000 and provide a premium supply of Iso-Sport products to Altis athletes.  Isodiol will make annual cash payments to Altis in the amount of US$125,000, based upon the achievement of certain performance milestones.

For more information on Isodiol, please visit www.isodiol.com

For more information on Altis, please visit www.altis.world

About Isodiol International Inc.

Isodiol International Inc. is the market leader in pharmaceutical grade pure, natural CBD and the industry leader in the manufacturing and development of CBD consumer products.

Isodiol is the pioneer of many firsts in the CBD industry, including the commercialization of 99%+ pure, natural isolated CBD, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products. Most recently, the Company received approval for its CBD designated as an Active Pharmaceutical Ingredient for use in Finished Pharmaceutical Products, as was announced on April 26, 2018.

Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and continued international expansion into Latin America, Asia, and Europe.

Follow Isodiol and Iso-Sport On Social Media: @isodiol / @isosportnow

https://www.facebook.com/isodiol/
https://www.facebook.com/isosportnow/
https://www.instagram.com/isodiol/
https://www.instagram.com/isosportnow/

About ALTIS

From coaching, to integrated support services, to education, to the athlete experience – ALTIS provides an environment in which the elite track and field athlete can grow.  ALTIS exists to help to shape the careers of the best athletes in the world, building championship performers. As part of this overarching aim, we are committed to an education program which nurtures and develops both coaches and athletes within our sport, assuring professionalism and continued growth at all levels of athletic development. Our sport is the best in the world, and it deserves a home and caretaker: ALTIS was built to bring Track & Field back to global prominence through the unification of the sport and the construction of a new Track & Field that thrives and is self-sustaining: This global vision is massive and overreaching – and this is unabashedly our vision and future.

For more information visit https://altis.world/

ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director

INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com

Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future of the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.

The CSE has not reviewed, approved or disapproved the content of this press release.

Click here to connect with Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”) for an Investor Presentation. 

Source: globenewswire.ca